Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China

OBJECTIVE: The aim of this article is to evaluate the cost-effectiveness of abemaciclib plus endocrine therapy (ABE + ET) vs. ET as adjuvant treatment for high-risk hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2–) early breast cancer in China. METHODS: From...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Qiran, Xu, YuTing, Liu, Wei, Guan, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683222/
https://www.ncbi.nlm.nih.gov/pubmed/38012661
http://dx.doi.org/10.1186/s12962-023-00499-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683222/
https://www.ncbi.nlm.nih.gov/pubmed/38012661
http://dx.doi.org/10.1186/s12962-023-00499-9

Ejemplares similares